3Etmisnan M , Wright JM, Carleton BC. Evidence - based Pharmacotherapy: Review of Basic Concepts and Applications in Clinical Practice. The Annals of Pharmacotherapy ,1998; 32(11): 1193
5Menon D , Scheubert F, Torrance G.W. Canada new guildlines for economics evaluation of pharmaceceticals. Medical Care. 1996; 12 (supplement): 77
6Schulman KA, Linas B P. Pharmacoeconomics : State of the art in 1997. AmmuRev- Pubic Health , 1997; 18:529
7Einarson TR. Pharmacoeconomic applications of meta- analysis for singlegroups using antifungal onychomycosis lacquers as an example. Clin. Ther, 1997;19(3): 559
8Jaeschke R, Guyatt G, Shannon H, et al. Basis statistics for clinicians: assessing the effects of treatment measures of association. Can Med Assoc J, 1995;152:351 ～ 357
9[1]Glennie JL, Torrance GW,Baladi JF, et al. The revised Canadian guidelines for the economic evaluation of pharmaceuticals[J]. Pharmacoeconomics,1999,15(5):459
10[3]Johanna Cook,Jeff Richardson,Andrew Street, et al. A cost utility analysis of treatment options for gallstone disease: methodological issues and results[J]. Health Econ,1994 ,3(3):157
